CTTI Highlights Multi-stakeholder Perspectives in Drug Development at Upcoming Clinical Investigator Course

On November 4 – 6, 2014 the FDA’s Office of Medical Policy and the Duke School of Medicine will co-sponsor the Sixth Annual Clinical Investigator’s course in College Park, MD.

This extensive 3-day course focuses on nonclinical, early clinical, and phase 3 studies; issues in the design and analysis of trials; safety and ethical considerations; and FDA’s regulatory requirements related to the performance and evaluation of clinical studies. (fda.gov)

During this event, CTTI will be represented in the Session 6 Roundtable titled The Clinical Investigator’s Role in Drug Development: a multi-stakeholder perspective at 2:15 pm on Thursday, November 6. To view the agenda for the entire program, click here.

We look forward to connecting with our colleagues at this event.

CTTI Tackles 3 Issues in Clinical Trials with New Projects

At CTTI, we are continuously looking for practices that will increase the quality and efficiency of clinical trials. In 2014, three new topics have been added to our portfolio:

  1. Conducting Trials Using Data Registries: Demographic, disease, and outcome data collected in clinical observational registries often overlap with data gathered for clinical trials. Integrating clinical trials within observational data registries may offer opportunities to avoid duplicative data collection and increase efficiency while decreasing clinical trial costs. Objectives for this project include identifying upfront costs and operational adjustments required to utilize a data registry for a clinical trial, as well as recommending best practices for conducting randomized registry trials.
  2. Data Monitoring Committees (DMCs): As the use of DMCs has increased and evolved over the past 40 years, critical issues have emerged. A few of these issues include differences in DMC roles and responsibilities, which contributes to confusion and unclear expectations, as well as a lack of a clear plan for preparing the next generation of DMC members. Objectives for this project include understanding the current landscape of DMC use and conduct, clarifying the purpose of and rationale for using a DMC, and describing effective communication practices between independent DMCs and other trial stakeholders.
  3. Investigator Turnover: While an enormous amount of time and resources are spent initiating new investigators into the clinical trial process, there continues to be a high turnover rate for investigators. As many as 40% of investigators annually choose not to participate in another FDA-regulated trial. This high rate of attrition impacts site and overall trial performance. Objectives for this project include obtaining a more thorough understanding of the factors that influence investigators’ decisions to leave the clinical research practice, as well as defining the impact of investigator turnover on industry and society.

 

CTTI’s #DIA2014 Posters Available Online

On June 15-19, the DIA hosted their 50th Annual Meeting (also known as #DIA2014) in San Diego, CA. Several CTTI members and staff attended the conference, and were involved with panels, workshops and poster presentations. We are now pleased to share the posters from this event on our website:

  1. A Collaboration to Facilitate the Development of Antibacterial Agents for Unmet Need: Streamlining Clinical Trial Protocols
    Abstract Summary: This collaboration includes the participation of a multi-disciplinary working group led by CTTI. Several meetings and workshops were held to gain a wider understanding of issues, several solutions using a Quality by Design approach were proposed.
    Presenter: Gary Noel, MD, Senior Director for Janssen Research and Development
  2. Good Clinical Practice (GCP) Training: Identifying Key Elements and Strategies for Increasing Training Efficiency
    Abstract Summary: CTTI convened a multidisciplinary working group involving partners from academia, industry, and government to develop recommendations for streamlining current GCP training efforts.
    Presenter: Jonathan Seltzer, MD, MA, MBA, FACC, President and CEO for Applied Clinical Intelligence, LLC

We would like to thank our colleagues in attendance at #DIA2014 who contributed to this successful conference, and we look forward to seeing you at #DIA2015.

Executive Summary of the CTTI-Hosted Expert Meeting on Good Clinical Practices Now Available Online

GCP Training Expert Panel

On January 31, 2014, CTTI convened a diverse array of thought leaders from the clinical trials enterprise to discuss good clinical practice (GCP) training. The goal of this meeting was to seek consensus on the key elements of GCP training, as well as the frequency, format, and competency of training required to conduct clinical studies in the United States. We are now pleased to share the executive summary from this meeting online. For more information on this expert meeting, including the participant list and presentations, CLICK HERE.

This meeting is a part of CTTI’s ongoing GCP Training Project. For more information on this project, CLICK HERE.